ZAP-70 Expression in B-Chronic Lymphocytic Leukemia in Sudanese Patients

Abdelgader, Enaam Abdelrhman; Eltayeb, Nada Hassan; Eltahir, Tasniem Ahmed; Altayeb, Osama Ali; Fadul, Eman Abbass; Rahman, Eldirdiri M. Abdel; Merghani, Tarig H

doi:10.18502/sjms.v13i4.3593

Cited by 2 publications

(4 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The lower Percentage of ZAP-70 + patient presented at low risk (0) Rai stage compared to ZAP-70 − patients (5.6% and 10.8%, respectively) indicated much aggressive disease at presentation in ZAP-70 + patient, but was statistically insignificant. While Hus et al [26], Schroers et al [16], D’arena et al [27], Del Giudice et al [25] and Waheed et al [28] found that there were significant correlations of ZAP-70 with stage at presentation, our study found no such associations (Additional file 1: Table S3), similar to study that reported by Abdel-Gader et al [23], and Gogia et al [29].…”

Section: Discussionsupporting

confidence: 90%

“…Considering ZAP-70, using 20% as the cutoff for positivity, 36/110 (32.7%) of our patients had positive ZAP-70 expression. Nearly similar distribution was seen by Del Giudice et al [25], Hus et al [26], D’arena et al [27] (28%, 36.5% and 36% respectively), whereas Waheed et al [28] reported higher expression (60%) but Gogia et al [29] and Abdel-Gader et al [23] reported lower expression (25%) and (22.6%) in India and Sudan, respectively. According to meta-analysis done by Liu et al [30] the role of ZAP-70 expression in the prognosis of B-CLL is unaffected by region.…”

Section: Discussionsupporting

confidence: 77%

“…Absolute B lymphocyte count was obtained by flow cytometry. Expression of ZAP-70 and CD38were performed by flow cytometry, as previously described [18, 23, 24].…”

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Combined analysis of ZAP-70 and CD38 expression in sudanese patients with B-cell chronic lymphocytic leukemia

et al. 2019

Self Cite

View full text Add to dashboard Cite

Objective To investigate the ZAP-70 and CD38 expressions and their combined expressions in Sudanese B-CLL patients and their relationships with clinical and hematological characteristics as well as the disease staging at presentation. Results In the present cross-sectional descriptive study, analysis of ZAP-70 expression showed that 36/110 (32.7%) patients positively expressed ZAP-70 and insignificant higher presentation in intermediate and at advanced stages as well as no correlation was seen with hematological parameters and clinical features compared with negatively ZAP-70, on the other hand, 41/110 (37.3%) were CD38 + and no significant correlation was shown with the stage at presentation, clinical characteristics (except Splenomegaly, P = 0.02) and hematological parameters. However, in combined expressions of both ZAP-70 and CD38 together, 20/110 (18.2%) were concordantly ZAP-70 + /CD38 + , 53/110 (48.2%) concordantly ZAP-70 − /CD38 − and 37/110 (33.6%) either ZAP-70 + or CD38 + , and these three groups showed insignificant correlation with clinical (except Splenomegaly, P = 0.03) and hematological parameters, and the stage at presentation. Our data showed the combined analysis of these two markers, lead to classify our patients into three subgroups (either concordant positive, negative or discordant expressions) with statistically insignificant correlation with clinical presentation (except Splenomegaly), hematological parameters and stage at presentation of B-CLL patients. Electronic supplementary material The online version of this article (10.1186/s13104-019-4319-8) contains supplementary material, which is available to authorized users.

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Discussionsupporting

confidence: 77%

See 1 more Smart Citation

Combined analysis of ZAP-70 and CD38 expression in sudanese patients with B-cell chronic lymphocytic leukemia

et al. 2019

Self Cite

View full text Add to dashboard Cite

show abstract

“…The disease can progress quickly in some patients and result in early death, but in others, it remains stable without the need for treatment and lasts for several years . 3,4 To identify stable or progressive forms of CLL, other prognostic factors should be considered in the early stages of the disease. 5 Somatic mutations in the immunoglobulin heavy-chain variable region (IgVH) are among the most influential…”

mentioning

confidence: 99%

Expression of ZAP 70 in Chronic Lymphocytic Leukemia (CLL) and its Correlation with Clinical Stages

Tasleem,

Malik,

Shaukat

et al. 2024

J. Bahria Uni. Med. Dent. Coll.

View full text Add to dashboard Cite

Objective: To ascertain the levels of ZAP-70 expression within the context of Chronic Lymphocytic Leukemia (CLL) patients and to subsequently analyze the potential correlations between ZAP-70 expression and the clinical staging of the disease. Study Design & Setting: Cross-sectional, descriptive study. Department of Hematology, Armed Forces Institute of Pathology (AFIP), Rawalpindi from July 2021 to December 2021. Methodology: We included 73 CLL patients of various ages and both genders. and patients having lymphoproliferative disorders other than CLL were excluded. Sysmex XN-3000 was used to do complete blood counts. Diagnosis of CLL was confirmed immunophenotypically by flow cytometry. Samples were processed by standard methods for ZAP70 analysis. Descriptive statistics were expressed in terms of mean ± standard deviation (SD). A Chi-square test was conducted, with a significance level of p-value =0.05 being considered significant. Results: Among 73 patients, 24 were females (32.9%) and 49 were males (67.1%). Females had a mean age of 69.00±9.47 years, whereas males had a mean age of 65.73±11.12 years. ZAP-70 expression was positive in 8 (11%) and negative in 65 (89.0%) cases. The expression of ZAP-70 in CLL and its correlation with Binet Stages was significant (p=0.002). ZAP- 70 expression in males and females showed no significant difference (p 0.059). ZAP-70 analysis showed no significant difference in patients with age more than 60 years from = 60 years of age (p= 0.275) Conclusion: ZAP-70 gene expression should be used in routine laboratory settings and can be correlated with the clinical stages of CLL.

show abstract

ZAP-70 Expression in B-Chronic Lymphocytic Leukemia in Sudanese Patients

Cited by 2 publications

References 29 publications

Combined analysis of ZAP-70 and CD38 expression in sudanese patients with B-cell chronic lymphocytic leukemia

Combined analysis of ZAP-70 and CD38 expression in sudanese patients with B-cell chronic lymphocytic leukemia

Expression of ZAP 70 in Chronic Lymphocytic Leukemia (CLL) and its Correlation with Clinical Stages

Contact Info

Product

Resources

About